CXC chemokine ligand 1 mediates adiponectin-induced angiogenesis in ovarian cancer

• Published in: Tumor biology Vol. 41; no. 4; pp. 1010428319842699 - 782
• Main Authors: Ouh, Yung-Taek, Cho, Hyun Woong, Lee, Jae Kwan, Choi, Song Hee, Choi, Hyun Jin, Hong, Jin Hwa
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 01-04-2019; Sage Publications Ltd; IOS Press
• Subjects: Adiponectin; Adiponectin - genetics; Adiponectin - metabolism; Angiogenesis; Cell Line, Tumor; Cell Movement - genetics; Chemokine CXCL1 - genetics; Chemokines; CXC chemokines; Female; Human Umbilical Vein Endothelial Cells; Humans; Neoplasm Invasiveness - genetics; Neovascularization, Pathologic - complications; Neovascularization, Pathologic - genetics; Neovascularization, Pathologic - pathology; Ovarian cancer; Ovarian Neoplasms - complications; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; RNA, Small Interfering - genetics; Vascular Endothelial Growth Factor A - genetics; CXC chemokine ligand 1; ovarian cancer; angiogenesis; Adiponectin
• ISSN: 1010-4283; 1423-0380
• DOI: 10.1177/1010428319842699

Objectives:
Adiponectin is a cytokine secreted from adipose tissue that regulates energy homeostasis, inflammation, and cell proliferation. Obesity is associated with increased risk of various cancers, including ovarian cancer. Adipokines, including adiponectin, have been implicated as a factor linking obesity and carcinogenesis. The oncogenic role of adiponectin is not known with regard to various cancer types. We sought to determine the role of adiponectin in angiogenesis in ovarian cancer in vitro.
Methods:
We transfected SKOV3 cells with vascular endothelial growth factor small interfering RNA in order to identify the independent angiogenic role of adiponectin in ovarian cancer. The vascular endothelial growth factor knockdown SKOV3 cell lines were treated with adiponectin for 48 h. The cytokines involved in adiponectin-mediated angiogenesis were explored using the human angiogenesis cytokine array and were verified with the enzyme-linked immunosorbent assay. The angiogenic effect of adiponectin was evaluated using the human umbilical vein endothelial cell tube formation assay. We also investigated the effects of adiponectin treatment on the migration and invasion of SKOV3 cells.
Results:
The number of tubes formed by human umbilical vein endothelial cell decreased significantly after knockdown of vascular endothelial growth factor (via transfection of vascular endothelial growth factor small interfering RNA into SKOV3 cells). When these vascular endothelial growth factor knockdown SKOV3 cells were treated with adiponectin, there was an increase in the number of tubes in a tube formation assay. Following adiponectin treatment, the CXC chemokine ligand 1 secretion increased in a cytokine array. This was confirmed by both enzyme-linked immunosorbent assay and Western blot. The increased secretion of CXC chemokine ligand 1 by adiponectin occurred regardless of vascular endothelial growth factor knockdown. In addition, the induction of migration and invasion of SKOV3 cells were significantly stronger with adiponectin treatment than they were without.
Conclusion:
Adiponectin treatment of ovarian cancer cells induces angiogenesis via CXC chemokine ligand 1 independently of vascular endothelial growth factor. These findings suggest that adiponectin may serve as a novel therapeutic target for ovarian cancer.